Quiz 6

Question 1

Conjugated equine estrogens (Brand, Class, MOA)

Answer 1

Premarin. Estrogen Deriv. Modulate the pituitary secretion of gonadotropins, LH, and FSH through a neg feedback sys.

Question 2

Conjugated equine estrogens (Indication, Preg, Black Box)

Answer 2

Hypoestrogenism, tx of mod/severe vasomotor sx assoc with Menopause, Postmenopausal OA, GSM, hypogonadism, abnormal uterine bleeding, breast cancer. X. Endometrial cancer; CVD; breast cancer; dementia.

Question 3

Raloxifene (Brand, Class, MOA)

Answer 3

Evista. SERM. Can antagonize or block estrogen; prevents bone loss and has the potential to block some estrogen effects in the breast/uterine tissues.

Question 4

Raloxifene (Indication, Preg, Black Box)

Answer 4

Osteoporosis tx & ppx in postmenopausal; Ppx of invasive Breast cancer in postmenopausal. X. Increased risk of VTE, CVD.

Question 5

Tolteridine (Brand, Class, MOA)

Answer 5

Detrol LA. Anticholinergic agent. Competitive antagonist of muscarinic Rs; increases residual urine volume and decreases detrusor muscle pressure.

Question 6

Tolteridine (Indication, Preg, Black Box)

Answer 6

Overactive Bladder (sx of urge incontinence, urgency, frequency). No. None.

Question 7

Levothyroxine (Brand, Class, MOA)

Answer 7

Synthroid, Levoxyl. Thyroid product. Promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate/

Question 8

Levothyroxine (Indication, Preg, Black Box)

Answer 8

Hypothyroidism; pituitary thyrotropin-stimulating hormone suppresion. No. Wt reduction.

Question 9

Alendronate (Brand, Class, MOA)

Answer 9

Fosamax, Binosto. Bisphosphonate deriv. Inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in BMD.

Question 10

Alendronate (Indication, Preg, Black Box)

Answer 10

Tx/ppx osteoporosis, Paget disease. No. None.

Question 11

Risedronate (Brand, Class, MOA)

Answer 11

Actonel. Bisphosphonate. Inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in BMD.

Question 12

Risedronate (Indication, Preg, Black Box)

Answer 12

Tx/ppx of Osteoporosis, Paget Disease. No. None.

Question 13

Ibandronate (Brand, Class, MOA)

Answer 13

Boniva. Bisphosphonate deriv. inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in BMD.

Question 14

Ibandronate (Indication, Preg, Black Box)

Answer 14

Tx/ppx of Osteoporosis in post-menopausal females (Females only). No. None.

Question 15

Zoledronic Acid (Brand, Class, MOA)

Answer 15

Reclast, Zometa. Bisphosphonate deriv. inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in BMD.

Question 16

Zoledronic Acid (Indication, Preg, Black Box)

Answer 16

Reclast: tx/ppx of glucocorticoid-induced Osteoporosis, Zometa: Hypercalcemia of Malignancy; multiple myeloma & bone metastases from solid tumors. No. None.

Question 17

Teriparatide (Brand, Class, MOA)

Answer 17

Forteo. Parathyroid hormone analog. PTH mimic, includes stimulating osteoblast function, increasing GI Ca2+ absorption, and increasing renal tubular reabsorption of Ca2+; results in increased BMD, bone mass, and strength.

Question 18

Teriparatide (Indication, Preg, Black Box)

Answer 18

Tx of Osteoporosis (glucocorticoid-induced, men, postmenopausal women). No. Potential risk of osteosarcoma.

Question 19

Vitamin D (Brand, Class, MOA)

Answer 19

N/A. Vit D analog/fat solu vit. Replenishes vit D in body.

Question 20

Vitamin D (Indication, Preg, Black Box)

Answer 20

Vit D deficiency (hypothyroidism). No. None.